Jenscare Scientific Co. Ltd. has formally submitted the registration application for CE mark of its innovative transcatheter mitral valve repair (TMVr) system, JensClip. The device, designed for the treatment of severe mitral regurgitation, has also entered the registration review stage with the National Medical Product Administration (NMPA) in China, following the submission and acceptance of its application. The company continues to promote the registration process to address a wide range of clinical needs. No grant or funding from other organizations was mentioned.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jenscare Scientific Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251229-11968009), on December 28, 2025, and is solely responsible for the information contained therein.